U.S., Oct. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07217379) titled 'The DART DELIVER-02 Study' on Oct. 13.
Brief Summary: This research study aims to find out how safe and well tolerated the experimental study drugs are when given to persons with HIV (PWH) taking antiretroviral therapy (ART). The study treatments are MGD014 and MGD020, which are two antibodies developed specifically for HIV, and Vorinostat, an oral medication to help expose HIV in cells to the antibodies. The study will measure the impact of study treatment on non-active HIV in cells, and how long MGD014 and MGD020 stay in the body after they are given.
In this study, participants will be randomly assigned to one of three groups. A...